Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Primary Lymphoid Organs01:16

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns.

Haematologica·2026
Same author

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

LySeqST: a targeted sequencing assay for robust genomic classification of diffuse large B-cell lymphoma.

Blood advances·2026
Same author

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Blood advances·2026
Same author

IL1RAP antibody-drug conjugates potently target primary and metastatic disease in multiple oncofusion-driven cancers.

Cancer discovery·2026
Same author

Bleomycin omission in limited-stage classic Hodgkin lymphoma with negative PET scan after two cycles of ABVD.

Haematologica·2026
Same journal

BRAF Alterations in Chronic Lymphocytic Leukemia: Genomic Landscape, Co-Mutation Patterns, and Clinical Relevance.

Current hematologic malignancy reports·2026
Same journal

Targeting the BCR::ABL1 Kinase: Advances Beyond Imatinib in Chronic Myeloid Leukemia.

Current hematologic malignancy reports·2026
Same journal

Germline DDX41 Variants: Current Understanding and Future Directions.

Current hematologic malignancy reports·2026
Same journal

Clonal Signatures of Telomere Biology Disorders.

Current hematologic malignancy reports·2026
Same journal

Molecular Pathogenesis and Targeted Therapies for Myeloproliferative Hypereosinophilic Neoplasms.

Current hematologic malignancy reports·2026
Same journal

The Intricate Dance Between Inflammation and Myeloproliferative Neoplasms: From Origins to Outcomes.

Current hematologic malignancy reports·2026
See all related articles

Related Experiment Video

Updated: May 29, 2026

Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper (cTfh) Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry
07:39

Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper (cTfh) Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry

Published on: January 7, 2019

Update: peripheral T-cell lymphomas.

Kerry J Savage1

  • 1British Columbia Cancer Agency, Vancouver, BC, Canada. ksavage@bccancer.bc.ca

Current Hematologic Malignancy Reports
|September 29, 2011
PubMed
Summary
This summary is machine-generated.

Peripheral T-cell lymphomas (PTCLs) are aggressive cancers. Understanding their prognosis and developing new therapies are crucial for patient outcomes, with recent treatments showing promise.

Related Experiment Videos

Last Updated: May 29, 2026

Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper (cTfh) Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry
07:39

Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper (cTfh) Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry

Published on: January 7, 2019

Area of Science:

  • Oncology
  • Hematology
  • Immunology

Background:

  • Peripheral T-cell lymphomas (PTCLs) represent a diverse group of aggressive hematologic malignancies.
  • Understanding PTCLs has been challenging due to their rarity and the complexity of T-cell phenotypes.
  • The International Peripheral T-cell Lymphoma Project aimed to improve prognostic understanding.

Purpose of the Study:

  • To enhance the understanding of prognostic factors in Peripheral T-cell lymphomas.
  • To consolidate knowledge from a large collaborative effort on PTCLs.
  • To inform the development of improved therapeutic strategies.

Main Methods:

  • A large-scale collaborative project involving multiple institutions.
  • Analysis of a broad cohort of patients with Peripheral T-cell lymphomas.
  • Focus on T-cell phenotype and its impact on prognosis.

Main Results:

  • PTCLs are characterized by significant biological heterogeneity.
  • Disease rarity and T-cell phenotype complexity have historically hindered progress.
  • New therapeutic approaches are emerging with promising results.

Conclusions:

  • Improved understanding of PTCL prognosis is essential.
  • Collaborative research efforts are vital for advancing PTCL knowledge.
  • Recent therapeutic advancements offer hope for improved patient outcomes.